




**Company Information for  
BioTuesday  
Lyon 6 July 2010**

# Company Origin

2008



## About Poxel

- Biopharmaceutical company developing innovative first-in-class drugs with a primary focus on Type 2 diabetes
- Develop drug candidates to clinical proof of concept before partnering with pharmaceutical partners, which will be responsible for late clinical development and commercialization stages
- Strong reliability on partnerships to feed and progress the pipeline
- Operates completely independently as a lean organization with strong in-house drug development expertise
- Series A Financing to Accelerate Pipeline Development

# Products and Team


Poxel products target metabolic diseases, providing:

- An innovative and disease modifying mechanism of action
- A combined activity on glucose metabolism and other cardiovascular risk factors (lipid disorders and obesity)
- An improved safety profile compared to currently available therapies

The management team has an integrated strategic and operational view of the product value chain, from research to marketing:

- Covering the total product life cycle
- Anticipating and focusing streamline development up to proof of clinical concept to allow out-licensing deals
- Triggering one purpose: full quality management to mitigate risks associated to innovative products development

# Business Model



# Type 2 Diabetes Epidemiology


## Diabetes Prevalence Worldwide (source IDF)

**2000 : 170 million people**

**2030 : 366 million people**

- More than 2-fold increase in 30 years !!
- 30% of obese people
- High prevalence in emerging countries adopting western life style
- Elderly people increasing in western countries
- Increased prevalence in young people due to settled way of life and high calories food intake


# Type 2 Diabetes: an Ever Attractive Market



\* F, G, UK, I, Sp

# Still a Lot of Unmet Needs


- T2DM is an non cured disease
- People die from CV complications





# Imeglimin Target Product Profile

- 1<sup>st</sup> Representative of a new class, the Glimins
- An innovative mechanism: target the 3 key defects of diabetes:
  - Insulin resistance
  - Overproduction of glucose by the liver
  - Insulin deficiency from pancreatic beta cells
- An efficacy comparable to gold standard Metformin




# Imeglimin Target Product Profile

- An excellent safety and tolerability profile

Phase IIa study	Placebo	Imeglimin low	Imeglimin high	Metformin 850
Patient with TEAE Number (%)	11/33 (33%)	5/31 (16%)	6/31 (19%)	13/33 (39%)

- An appropriate treatment for sensitive populations (renal impairment, elderly and pediatric populations)
- A combinable drug to other anti-diabetic treatments, to insulin and to treatments for co-morbidities



=> All claims translating into an enhanced benefit/risk ratio

# Imeglimin is Expected to Take Shares from Metformin, SU and TZDs in the Current Environment



Cumulated % per class:

22%

30%

16%

39%

38%

1%


5%

16%

3%

20%

25%



Products expected to be replaced by Imeglimin [products >5% shown]

20% of physicians think Imeglimin will be another option in their armamentarium



[www.poxel.com](http://www.poxel.com)

**Head Office:**  
200 avenue Jean Jaurès  
69007 Lyon  
France

Tel: +33 4 37 37 20 10  
Fax: +33 4 37 70 88 15

[contact@poxelpharma.com](mailto:contact@poxelpharma.com)